The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer.
Min-Hee Ryu
No relevant relationships to disclose
Baek-Yeol Ryoo
No relevant relationships to disclose
Young Soo Park
No relevant relationships to disclose
Sook Ryun Park
No relevant relationships to disclose
Jong Gwang Kim
No relevant relationships to disclose
Hye-Suk Han
No relevant relationships to disclose
Ik-Joo Chung
No relevant relationships to disclose
Eun-Kee Song
No relevant relationships to disclose
Kyung Hee Lee
No relevant relationships to disclose
Seok Yun Kang
No relevant relationships to disclose
Yoon-Koo Kang
Consultant or Advisory Role - Bayer (U); Novartis (U); Roche (U); Sanofi (U)
Research Funding - Bayer; Novartis; Roche